Description
HUMANA PRESS Sensitization Of Cancer Cells For Chemo Immuno Radio-Therapy 2008 Edition by BENJAMIN BONAVIDA
This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies. Table of ContentsPrefacePart I. Sensitization via membrane-bound receptors1. Sensitization of epithelial cancer cells with human monoclonal antibodiesPeter Vollmers and Stephanie Brandlein2. Targeting the transferrin receptor to overcome resistance to anti-cancer agentsTracy R. Daniels, Isabel I. Neacato, Gustavo Helguera, Manuel L. Penichet3. Chemo-immunosensitization of resistant B-NHL as a result of rituximab (anti CD20 mAb)-mediated inhibition of cell survival signaling pathwaysBenjamin Bonavida, Ali R. Jazirehi, Mario I. Vega, Sara Huerta-Yepez, Kazuo Umezawa, and Eriko Suzuki4. Agents that regulate DR5 and sensitivity to TRAILTatsushi Yoshida and Toshiyuki Sakai5. Proteasome inhibition: Potential for sensitization of immune effector mechanisms in cancerMilad Motarjemi, William H.D. Hallett, Minghui Li, and William J. MurphyPart II. Sensitization via inhibition of cell survival pathways (excluding apoptotic signaling pathways)6. Angiogenesis inhibitors as chemosensitizing agents for the treatment of metastatic diseaseGiulio Francia, Urban Emmenegger, and Robert S. Kerbel.7. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK and P13K/Akt pathways to sensitize cancer cells to therapyJames A. McCubrey, Richard A. Franklin, Fred E. Bertrand, Jackson R. Taylor, illiam H. Chappell, Melissa L. Midgett, Ellis WT. Wong, Stephen L. Abrams, ristin M. Stadelman, Negin Misaghian, Dale E. Lugwid, Jorg Basecke, Massimo ibra, Franca Stivala, Michele Milella, Agostino Tafuri, Alberto M. Martelli, aolo Lungi, Antonio Bonati, David M. Terrian, Brian D. Lehmann, and Linda S. Steelman8. Histone deacetylase inhibitors and anti-cancer activityRoberto R. Rosato and Steven Grant9. Eicosanoids and resistance of cancer cells to chemotherapeutic agents Andrey SorokinPart III. Sensitization via transcription factors 10. The RKIP and STAT3 axis in cancer chemotherapy: opposites attractDevasis Chatterjee, Edmond Sabo, Murray B. Resnick, Kam C. Yeung, and Y. Eugene Chin11. Targeting transcription factors with decoy oligonucelotides: modulation of the expression of genes involved in chemotherapy resistance of tumor cellsRoberto Gambari12. p53 inhibitors as cancer sensitizing agentsFlavio Maina and Rosanna Dono13. Nitric Oxide-Induced Immunosensitization to Apoptosis by Fas-L and TRAILBenjamin Bonavida, Sara Huerta-Yepez, Mario I. Vega, Demetrios A. Spandidos and Stravoula Baritaki14. Natural agents that can sensitize tumor cells to chemotherapy and radiation therapyGanesh Jagetia, Sunil Krishnan, and Bharat B. AggarwalPart IV. Sensitization via targeting apoptotic pathways15. Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agentsDaniel E. Johnson16. Therapeutic targeting of apoptosis in cancerTimothy R. Wilson, Daniel B. Longley, and Patrick G. Johnston17. Peptides and peptidomimetics as cancer therapy sensitizing agentsShantanu Banerji, Sudharsana Rao Ande, Subbareddy Maddika, Versha Banerji, Iran Rashedi, Neil W. Owens, Anne Zuse, Frank Schweizer, and Marek Los18. Nonpeptidic mimetics as cancer sensitizing agentsRuud P.M. Dings, Mark Klein, and Kevin H. Mayo19. Sensitization of cancer cells to cancer therapies by isoflavone and its synthetic derivativesFazlul H. Sarkar and Yiwei Li20. Antisense oligonucelotides and siRNA as specific inhibitors of gene expression: mechanisms of action and therapeutic potentitial; AS-ODN and siRNA: mechanisms and therapeutic potentialYvonne Foerster and Bernd SchwenzerPart V. Sensitization tailored to individual patients21. DNA